Display Settings:

Format

Send to:

Choose Destination
    Hosp Med. 2002 Jul;63(7):421-5.

    TOBI: reducing the impact of pseudomonal infection.

    Source

    Department of Medical Microbiology, University of Edinburgh Medical School, Edinburgh EH8 9AG.

    Abstract

    Pseudomonas aeruginosa infection is associated with impaired lung function and reduced life expectancy in cystic fibrosis patients. Tobramycin nebulizer solution (TOBI, Chiron Corporation Ltd, Hounslow) has been specifically formulated for use against P. aeruginosa infection in the lung.

    PMID:
    12187603
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk